

# Chiara Pavanello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/427385/publications.pdf>

Version: 2024-02-01

24  
papers

661  
citations

566801

15  
h-index

642321

23  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1001  
citing authors

#	ARTICLE	IF	CITATIONS
1	The HDL mimetic CERâ€001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency. <i>Journal of Internal Medicine</i> , 2022, 291, 364-370.	2.7	11
2	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet</i> , The, 2022, 399, 719-728.	6.3	69
3	Plasma FA composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans. <i>Journal of Lipid Research</i> , 2022, 63, 100232.	2.0	4
4	Two novel variants in the lecithin:cholesterol acyltransferase gene resulted in classic LCAT deficiency. <i>Atherosclerosis Plus</i> , 2022, , .	0.3	0
5	Vasculoprotective properties of plasma lipoproteins from brown bears ( <i>Ursus arctos</i> ). <i>Journal of Lipid Research</i> , 2021, 62, 100065.	2.0	5
6	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red) Tj ETQq0 0.0 rgBT /@verlock 10	0.0	0
7	Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 463-468.	1.3	13
8	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. <i>Atherosclerosis</i> , 2020, 312, 72-78.	0.4	25
9	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Biomedicines</i> , 2020, 8, 625.	1.4	21
10	The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL. <i>PLoS ONE</i> , 2020, 15, e0229322.	1.1	4
11	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. <i>Atherosclerosis</i> , 2020, 297, 8-15.	0.4	12
12	Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. <i>Journal of Lipid Research</i> , 2020, 61, 1784-1788.	2.0	19
13	Familial LCAT deficiency and cardiovascular disease: the game is not over. A case of dramatic multivessel atherosclerosis. <i>Minerva Medica</i> , 2020, , .	0.3	1
14	Nutraceutical approach for the management of cardiovascular risk â€“ a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. <i>Nutrition Journal</i> , 2019, 18, 13.	1.5	37
15	Autosomal Recessive Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 71, 279-288.	1.2	38
16	Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. <i>European Journal of Nutrition</i> , 2018, 57, 499-511.	1.8	49
17	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. <i>Advances in Therapy</i> , 2017, 34, 1200-1210.	1.3	56
18	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. <i>Journal of Lipid Research</i> , 2017, 58, 994-1001.	2.0	18

#	ARTICLE	IF	CITATIONS
19	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
20	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
21	Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial. <i>Journal of Functional Foods</i> , 2017, 37, 8-15.	1.6	22
22	High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis. <i>Endocrinology and Metabolism</i> , 2016, 31, 223.	1.3	35
23	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. <i>Journal of Clinical Lipidology</i> , 2015, 9, 226-233.	0.6	22
24	Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. <i>Journal of Clinical Lipidology</i> , 2014, 8, 61-68.	0.6	74